ArticleJournal of molecular histology2025
hsa_circ_0099682 exacerbates the development of diabetic retinopathy by promoting pathological neoangiogenesis via the miR-125b-5p/HNRNPU axis.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveDiabetic retinopathy (DR) is a leading cause of vision loss, driven by hyperglycemia-induced human retinal microvascular endothelial cell (HRMEC) dysfunction, mitochondrial impairment, oxidative stress, inflammation, and aberrant angiogenesis. Circular RNAs (circRNAs) have emerged as critical regulators in various ocular pathologies, yet their contributions to DR remain unclear. This study identified and characterized hsa_circ_0099682, derived from the alpha motif domain-containing protein 1B (ANKS1B) gene, and investigated its role and molecular mechanism in high glucose (HG)-induced HRMEC injury.
methodsHsa_circ_0099682 was validated as a genuine circRNA through bioinformatic analyses (circPrism, circBank), RNase R digestion, actinomycin D treatment, and PCR with divergent/convergent primers. HG-exposed HRMECs were transfected with siRNAs targeting hsa_circ_0099682, miR-125b-5p inhibitors, or heterogeneous nuclear ribonucleoprotein U (HNRNPU) overexpression constructs. Mitochondrial function was assessed by reactive oxygen species (ROS) measurement and JC-1 staining for mitochondrial membrane potential. Inflammatory and oxidative stress markers (interleukin [IL]-6, IL-1β, superoxide dismutase [SOD], and malondialdehyde [MDA]) were quantified by enzyme-linked immunosorbent assay (ELISA) and commercial kits. Apoptosis and tube formation assays evaluated cell survival and angiogenic potential. Luciferase reporter and RNA immunoprecipitation assays confirmed ceRNA interactions. streptozotocin-induced DR rats were treated with AAV-shRNA to silence hsa_circ_0099682. Hematoxylin and eosin staining, immunofluorescence, ELISA, and Western blot analyses were performed to assess retinal structure, inflammation, oxidative stress, and angiogenic markers.
resultsHsa_circ_0099682 showed stable circular configuration and abundant cytoplasmic localization. In HG-stressed HRMECs, hsa_circ_0099682 knockdown reduced ROS accumulation, preserved mitochondrial membrane potential, diminished IL-6 and IL-1β secretion, enhanced antioxidant capacity, lowered apoptosis, and suppressed tube-forming ability. Mechanistically, hsa_circ_0099682 functioned as a sponge for miR-125b-5p, thereby relieving miR-125b-5p-mediated repression of HNRNPU. Inhibiting miR-125b-5p or overexpressing HNRNPU reversed the protective effects of hsa_circ_0099682 knockdown. In DR rats, silencing hsa_circ_0099682 improved retinal structural integrity, mitigated inflammation and oxidative stress, and restored balance in angiogenesis-related protein expression.
conclusionHsa_circ_0099682 accelerates DR progression by suppressing miR-125b-5p, enhancing HNRNPU expression, and inducing mitochondrial dysfunction, inflammation, and irregular neoangiogenesis.
Indexed as
Identifiers
40782251What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.